WuXi Healthcare Forum 2019: Meeting Tomorrow’s Health Challenges

The opening day agenda focuses on novel medicines. We will explore how science, technology and entrepreneurship is driving a new age of geographically dispersed innovators, operating internationally to “bridge productivity” and expedite the development of better medicines.

7:30 AM - 9:00 AM

Breakfast & Registration

9:00 AM - 9:05 AM

Welcome

9:05 AM - 9:20 AM

Opening Remarks

Ge Li, Chairman, WuXi AppTec Group

9:20 AM - 10:00 AM

New Era. Golden Opportunities. 

Leaders from China and the UK explore how key stakeholders are redefining the innovation narrative – opening up a new era of opportunities and connecting the global ecosystem.

Ruilin Song, Executive President, China Pharmaceutical Innovation and Research Development Association

Steve Bates, CEO, UK BioIndustry Association

Leon Wang, Executive Vice President, International and China President of AstraZeneca

Edward Hu, Co-CEO, WuXi AppTec

Moderated by Kevin Holland, Minister-Counsellor and Director of Life Sciences, Healthcare and Social Care for China, British Embassy Beijing

10:00 AM - 10:40 AM

Medicines for Global Impact

The development of tomorrow’s therapies has no boundaries. This session discusses how companies can work across borders and across technologies to bring about transformational changes wherever they can have the greatest impact.

Yongjun Liu, Global Head of Research, Sanofi

Lianshan Zhang, President, Global R&D, Jiangsu Hengrui Medicine Co.

George Chen, Sr. VP, Global R&D Oncology Unit; Head, R&D China, AstraZeneca

Harald Reinhart, Chief Medical Officer, Autoimmune & Infectious Diseases, Zai Laboratory

Damian O’Connell, CEO, Experimental Drug Development Centre, A*STAR

Moderated by Steve Yang, EVP, CBO, WuXi AppTec

10:40 AM - 11:00 AM

“Academic-Industry Collaboration in HIV Product Development and Scientific Inquiry”

David Ho, Scientific Director and CEO, Aaron Diamond AIDS Research Center

History has shown it only takes one individual with a dream and dedication to make a difference. We hear from one such hero – David Ho.

11:00 AM - 11:20 AM

“Inflammation 2030 - Modern Diseases Caused by an Old Flame”

Zhijian "James" Chen, George L. MacGregor Distinguished Chair in Biomedical Science, UT Southwestern Medical Center

James Chen - winner of the prestigious 2019 Breakthrough Prize in Life Sciences - will discuss his insights on ‘innate immunity’, which answered a century old mystery of DNA, and most importantly, how we might harness its potential.

11:20 AM - 12:00 PM

Where is the Next Disruption?

It’s time for some big ideas. We ask these leaders if they had a magic wand. What are their radical ideas to disrupt and improve R&D?

Ram Sasisekharan, the Alfred H. Caspary Professor of Biological Engineering， Massachusetts Institute of Technology

Jane Osbourn, Vice President R&D, MedImmune, Chair UK BioIndustry Association

John Oyler, Chairman, Co-Founder & CEO, BeiGene

Michael Yi, Partner, Hillhouse Capital Group

Nisa Leung, Managing Partner, Qiming Venture Partners

Moderated by Ken Drazan, Co-founder and CEO, Arsenal Bio

12:00 PM - 13:30 PM

Lunch Break

13:30 PM - 14:00 PM

Insights on US and China Regulatory Development

An all-star panel of four former FDA/NMPA experts providing a spectrum of perspectives from small molecules to advanced therapies, and from quality to regulatory filing.

Ruyi He, Chief Scientific Officer, SDIC Fund Management

Michael Yi Yao, Co-Chairman, Gem Flower Pharma Tech 

Gang Wang, Vice President for Quality and Global Regulatory Affairs, WuXi Biologics

Moderated by Chiang Syin, Chief Quality Officer, WuXi Biologics

14:00 PM - 14:40 PM

How to Deliver Global Success

The industry’s top practitioners discuss strategies to bring vital new medicines through the pipeline faster to patients at home and abroad.

Craig Anderson, Professor, University of New South Wales in Sydney; Executive Director, The George Institute for Global Health China

Zhengqing Li, VP and Head of China Development, MSD

Matt Cooper, Exec Director - Business Development & Marketing, National Institute for Health Research, UK

Carl Firth, CEO, ASLAN Pharmaceuticals

Jinzi J. Wu, Founder, Chairman and CEO, Ascletis Pharma

Moderated by James Xue, Chairman and CEO, CANbridge

14:40 PM - 15:00 PM

Coffee Break 

15:00 PM - 15:40 PM

The New Wave: Anti-Aging

Here, we discuss, as new understandings of aging come to light, what age-related diseases are becoming significantly more prevalent, and how are scientists and entrepreneurs taking new approaches to tackle them?

Alex Zhavoronkov, Founder and CEO, Insilico Medicine

Eric Morgen, COO and CMO, BIOAGE

Karen Reeves, President and CMO, AZTherapies

Sang Hoon Lee, Founder and CEO, ABL Bio

Zhenyu Ju, Dean, Institute of Aging and Regenerative Medicine, Jinan University

Guy Spigelman, VP Portfolio Success, aMoon Fund

15:40 PM - 16:20 PM

The New Wave: Anti-Cancer

A peek at some of the latest anti-cancer strategies and what impact can we expect them to have.

Ash Bahl, CSO and Head of R&D, Carrick Therapeutics

Binhe Xu, Director of the Department of Medical Oncology at the National Cancer Center, China

Zhengying Pan, Research Fellow, School of Chemical Biology & Biotechnology, Peking University

Simone Botti, CEO, MetaboMed

Sofie Qiao, President and CEO, Vivace Therapeutics

Darren Ji, Co-founder and CEO, Elpiscience; Venture Partner, Lilly Asia Ventures

16:20 PM - 17:00 PM

The New Wave: Technologies

New technologies are changing the face of R&D. How will our industry change in the next few years by taking full advantage of the opportunities technologies present?

Yanni Lin, Chief Technology Officer, CureGenetics

Jörg Weiser, Managing Director, Schrodinger

Misti Ushio, CEO, TARA Biosystem

Qi Liu, Professor, Bioinformatics Department in Tongji University

Naheed Kurji, President and CEO, Cyclica

During day two, we take a broader look at health beyond therapy alone. Tomorrow’s healthcare will go far further than prescribing drugs or performing surgery, it’s about bringing in the wider lens and tools to improve patient care. A new “networked ecosystem” will be built upon vertically elevating the industry’s strategy and horizontally harnessing our collective wisdom to break down silos, and act boldly on new thinking.

9:00 AM - 9:40 AM

A Special Tribute to the Era of Transformation

During this special session, we use China and Asia as examples of how innovation hubs are started, catalyzed, and grown into full vibrancy. A reflection on a few historical “firsts.” 

Daniel Auerbach, Senior Managing Partner, Eight Roads

William Keller, Chairman, Coland Pharmaceuticals 

Li Chen, CEO, Hua Medicine

Chris Chen, CEO, WuXi Biologics

Moderated by Greg Scott, Founder and CEO, ChinaBio

9:40 AM - 10:20 AM

The New Age of Global Innovation

The future will be defined by accelerated global connections and a networked ecosystem – whether from Boston to Osaka, or San Diego to Shanghai. But what new strategies are required for innovators to take advantage of global opportunities for product development, partnership and investment?

Dan Wang, Head of Johnson & Johnson Innovation, Asia Pacific

Curtis Keith, CSO, Blavatnik Biomedical Accelerator, Harvard University

Robert S. Sullivan, Dean, Rady School of Management, UC San Diego

Toshio Fujimoto, General Manager, Takeda Shonan Innovation Park, Takeda  

Sophie Sun, Managing Director, Merck Innovation Hub China

Moderated by David Flores, Co-Founder, President and CEO, BioCentury

10:20 AM - 10:40 AM

A Conversation with Ken Hitchner, Chairman and CEO, Asia Pacific Ex-Japan, Goldman Sachs

Now we zoom into the future of Asia Pacific - one of the most dynamic and diverse regions in the world with 60% of the world’s population, huge unmet health needs, and a large proportion of future global economic growth.

Moderated by Yibing Wu, Joint Head, Enterprise Development Group & Head, China, Temasek

10:40 AM - 11:20 AM

The Healthcare Disruption

How will we go about creating the robust platforms that ultimately will provide disruptive healthcare solutions? What the healthcare landscape might look like as it faces ever changing political and economic climate, and new technologies? 

Andy Lin, Founding Partner, Loyal Valley Capital

Lee Ligang Zhang, Founder, Chairman and CEO, iKang Healthcare Group

Leon Chen, CEO & Founding Partner, 6 Dimensions Capital

Shuyang Zhang, Vice President, Peking Union Medical College Hospital; Vice President, Chinese Academy of Medical Sciences & Peking Union Medical College

Jiangnan Cai, Director, CEIBS Centre for Health Care Management and Policy

Moderated by Feng Deng, Founding Managing Director, Northern Light Venture Capital

11:20 AM - 12:00 AM

Balancing Medical Innovation and Access

Across the world, accessibility and affordability are always at the center of the healthcare debate. How do we make sure patients get the healthcare they need? Can we balance costs and the need for innovation? Can big data and artificial intelligence help? This session provides a holistic appraisal from prominent players.

Rong Yu, Chairman, Meinian Onehealth Healthcare Group; Chairman, Tianyi Investment Group

Bin Li, Partner and Managing Director, Ally Bridge Group

Guang Ning, Vice President, Ruijin Hospital of Shanghai Jiaotong University

Chunpeng Hao, Deputy Secretary-General, China Health Insurance Research Association

Moderated by Wei Zhang, Chief Strategy Officer, WuXi AppTec

12:00 PM - 13:30 PM

Lunch Break

13:30 PM - 14:10 PM

Delivering Clinical Precision through Genomics

Genomics is finally ready for prime time. What does it mean to know what’s in your genes? What does genomic medicine mean for China? How do we bring about clinical precision and personalized medicine using genomic insights?

Wenhao Zhou, VP, Children’s Hospital of Fudan University

Gang Chen, CEO, WeGene

Shaokun Chuai, COO, Burning Rock Dx

Kai Wang, Founder and CEO, OrigiMed

Sijia Lu, CEO, Yikon Genomics

14:10 PM - 14:50 PM

Diagnosing the Future

Advanced Clinical Diagnostic testing has grown rapidly in recent years, and has become a key part of precision medicine. What are the latest trends in global diagnostic testing development? How can China’s Clinical Diagnostic sector learn from its global peers, and develop a unique path suitable for its patients? Where are the new markets and investment opportunities? How do we effectively build an ecosystem for future Diagnostics? 

William Morice, President, Mayo Clinic Laboratories

Daozhi Liu, Founding Partner, Sunland Capital

Martien van Osch, Managing Partner, Forbion

Yaoyi Zhu, Chairman, IVD Branch, China Association for Medical Devices Industry

Moderated by Jason Liu, CEO, WuXi Diagnostics

14:50 PM - 15:10 PM

Coffee Break 

15:10 PM - 15:30 PM

“Do’s and Don’t of Internet Healthcare Industry Development” 

Tiantian Li, Chairman and President, DXY

15:30 PM - 16:15 PM

The Data Inspiration

We postulate… How to improve data collection? Who owns data? How to break down the data silos? How will a data-driven future look like? 

Tony Zhang, Founder and CEO, LinkDoc Technology

Andy Liu, CEO, CW Data Technologies

Choo Chiap Chiau, AI Lab Director, Philips Research Asia

Hong Li, Vice President, Digital China Health Technologies

16:15 PM - 17:00 PM

The Patient Care Revolution 

The revolution in healthcare is being led by patients, who are now more empowered than ever. They are demanding more choice and transparency and harnessing technology to garner the best information to weigh their options and be in greater control of their care. What would tomorrow’s patient care look like? How will the newly empowered consumers drive disruption and change? And how we can navigate the path forward – using AI, machine learning and other technologies to transform public health?

Meng Zhang, General Manager, Tencent Health

Ning Hou, COO, XiKang

Xiaodong Tao, Vice President of iFlytek; CEO of iFlytek Healthcare

Fay Xing, CEO, PICA Health

Xinxin Gao, CEO and Founding Partner, Jiangmen

17:00 PM

Closing Remarks & Adjourn